Companies › Noorik Biopharmaceuticals
1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 4, 1 Phase 3; Cardiovascular, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ambrisentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06256432 | Ambrisentan | Phase 2 | Hepatorenal Syndrome | Gastroenterology | May 2026 |
| NCT07030894 | Ambrisentan | Phase 4 | IgA Nephropathy | Genitourinary | Dec 2026 |
| NCT07245680 | Ambrisentan | Phase 3 | Pulmonary Arterial Hypertension (PAH) | Cardiovascular | Feb 2029 |
Pharmazz Johnson & Johnson (Janssen) Novartis Travere Therapeutics AstraZeneca
Matrix Biomed Rege Nephro Livzon Pharmaceutical Group Novaliq Neurimmune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.